Fisher Asset Management
HRTX icon

Fisher Asset Management’s Heron Therapeutics HRTX Stock Holding History

Fisher Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-349,239
Closed -$405K – 1213
2023
Q2 		$405K Sell
349,239
-53,950
-13% -$96.2K ﹤0.01% 891
2023
Q1 		$609K Sell
403,189
-39
-0% -$98 ﹤0.01% 831
2022
Q4 		$1.01M Buy
403,228
+222,347
+123% +$716K ﹤0.01% 770
2022
Q3 		$763K Sell
180,881
-300
-0.2% -$1.17K ﹤0.01% 711
2022
Q2 		$505K Buy
181,181
+300
+0.2% +$1.21K ﹤0.01% 717
2022
Q1 		$1.03M Buy
180,881
+49,387
+38% +$361K ﹤0.01% 623
2021
Q4 		$1.2M Buy
131,494
+96,487
+276% +$985K ﹤0.01% 617
2021
Q3 		$374K Buy
35,007
+100
+0.3% +$1.22K ﹤0.01% 770
2021
Q2 		$542K Buy
34,907
+185
+0.5% +$2.94K ﹤0.01% 706
2021
Q1 		$563K Buy
34,722
+1,644
+5% +$29.3K ﹤0.01% 688
2020
Q4 		$700K Sell
33,078
-6,535
-16% -$114K ﹤0.01% 649
2020
Q3 		$587K Sell
39,613
-17,850
-31% -$279K ﹤0.01% 628
2020
Q2 		$845K Sell
57,463
-8,236
-13% -$135K ﹤0.01% 589
2020
Q1 		$771K Sell
65,699
-9,637
-13% -$181K ﹤0.01% 568
2019
Q4 		$1.77M Buy
75,336
+77
+0.1% +$1.7K ﹤0.01% 510
2019
Q3 		$1.39M Hold
75,259
– – ﹤0.01% 585
2019
Q2 		$1.4M Buy
75,259
+8,016
+12% +$160K ﹤0.01% 580
2019
Q1 		$1.64M Hold
67,243
– – ﹤0.01% 544
2018
Q4 		$1.74M Hold
67,243
– – ﹤0.01% 540
2018
Q3 		$2.13M Sell
67,243
-24,832
-27% -$925K ﹤0.01% 511
2018
Q2 		$3.58M Sell
92,075
-19,426
-17% -$618K ﹤0.01% 476
2018
Q1 		$3.08M Sell
111,501
-9,568
-8% -$217K ﹤0.01% 487
2017
Q4 		$2.19M Buy
121,069
+20,705
+21% +$338K ﹤0.01% 513
2017
Q3 		$1.62M Buy
+100,364
New +$1.57M ﹤0.01% 524

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return

Fisher Asset Management's HRTX Position: Q3 2023 in Review

Fisher Asset Management sold out of Heron Therapeutics (HRTX) in Q3 2023, closing a stake of 349,239 shares — an estimated $405K sold.

Fisher Asset Management first reported a position in HRTX in Q3 2017 and held it in 24 quarters. The position peaked at $3.58M in Q2 2018. 141 funds tracked by Wall St. Rank hold HRTX as of Q3 2023.

  • Fisher Asset Management reported no remaining Heron Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Fisher Asset Management sold 349,239 Heron Therapeutics shares in Q3 2023, an estimated $405K.
  • Fisher Asset Management first reported a position in Heron Therapeutics in Q3 2017 and held it in 24 quarters.
  • Fisher Asset Management's Heron Therapeutics position peaked at $3.58M in Q2 2018.
  • 141 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2023.

Based on Fisher Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.